SYDNEY--Australia-based pharmaceutical company CSL will expand its Illinois manufacturing facility under a previously announced $1.5 billion move to increase U.S. production. CSL, which produces ...

CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5-billion project.  | On Monday, CSL broke ground on an ...

CSL’s new Illinois investment adds to over $3B spent on U.S. operations since 2018. The expansion will create at least 300 ...

CSL, a global pharmaceutical manufacturer based in Melbourne, Australia, has broken ground on a $1.5 billion expansion of its campus in Kankakee, roughly 60 miles southwest of Chicago. The company has ...

CSL Behring setzt auf dynamische Prozesssimulation gekoppelt mit Live-Produktionsdaten für robustere Abläufe und höhere ...

Genezen reports that the company became the first CDMO to license CSL’s Cytegrity™ cell line production system that was designed for the production of lentiviral vectors (LVVs). “We have significant, ...

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...

The firm promises to produce millions of vaccine doses to in the case of an influenza pandemic.

The news: CSL has committed to a USD1.5 billion ($2.12 billion) expansion of its Illinois plasma therapy manufacturing facility, which it broke ground on Monday. The numbers: The Kankakee facility ...